Tag: Arthritis: Rheumatoid

Moderate evidence of small effect on disease progression seen for vitamin D, chondroitin, glucosamine for osteoarthritis

Existing sleep problems related mainly to disease-related measures, such as pain and reduced function, more so than disease duration

Prevalence of 24 of 44 previously defined morbidities and seven of 78 additional chronic disease categories significantly higher

No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept

Any DMARD use recorded at 56 percent of rheumatologist visits and 30 percent of primary care provider visits

Limited evidence suggests that continuing biological DMARDs may lower risk for disease flares without increasing risk for postop complications

Adverse events common during first year of methotrexate therapy for early rheumatoid arthritis, but most not serious

Substantial proportion of overall risk may be preventable by healthy lifestyle

Risk for severe progression higher for patients in top quintile for PRS; association stronger in patients who were younger at disease onset

Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met